CD276 and esophageal cancer: A recent study by Xuan et al. (22) reported the development of a CD276-targeting CAR-T cell that induced regression of esophageal cancer xenografts in mice and showed superior cytotoxicity and cytokine production than CD19-targeting CAR-T cells.